Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ZM336372 |
Synonyms | |
Therapy Description |
ZM336372 is a small molecule RAF1 inhibitor that paradoxically causes RAF1 activation through a putative feedback mechanism, resulting in decreased proliferation and cell cycle inhibition in carcinoid tumor cells (PMID: 20031160, PMID: 15956248). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ZM336372 | ZM 336372|ZM-336372 | CRAF Inhibitor 12 | ZM336372 is a small molecule RAF1 inhibitor that paradoxically causes RAF1 activation through a putative feedback mechanism, resulting in decreased proliferation and cell cycle inhibition in carcinoid tumor cells (PMID: 20031160, PMID: 15956248). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | high grade glioma | no benefit | ZM336372 | Preclinical - Patient cell culture | Actionable | In a preclinical study, ZM336372 treatment did not lead to inhibition of cell growth in a patient-derived glioma cell line harboring BRAF V600E in culture (PMID: 34433654). | 34433654 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|